DailyIQ
Last updated3 minutes ago

NBIX·Neurocrine Biosciences Inc.

$145.49
+1.28 (+0.89%)
Overnight$145.51+0.02 (+0.01%)
High
$145.77
Open
$145.56
Market Cap
14.68B
52W High
$193.25
Low
$141.39
P. Close
$145.49
P/E
20.80
52W Low
$122.13
Fwd P/E
12.25
DailyIQ Est.
$217.60
Inst. Ownership
0.4%
Short Interest
4.92%
Days to Cover
5.4
Technical Score (1D)
36
BEARISH
News Sentiment
63
BULLISH
On Oct 6, Guggenheim analyst Delma Caiati upgraded Neurocrine Biosciences to a Buy rating and announced a new price target of $207. The upgrade reflected confidence in the company’s pipeline and recent clinical progress. The new target represented a significant upside from current market levels, suggesting potential upside for investors. The upgrade signals confidence in pipeline progress.
LOW TARGET
$164 +12.7%
2 analysts
MEAN TARGET
$208 +42.8%
14 analysts
HIGH TARGET
$253 +73.9%
22 analysts
PRICE RANGE
$164.00 - $253.00
SB / B / H / S / SS
14/17/5/1/1
DAILYIQ EST.
$217.60 (+49.5%)
Bought (1Y)
0 shares
$0
Sold (1Y)
169,620 shares
$27.6M
ABERNETHY MATTChief Financial Officer
Sell2,311 shares2026-09-14
Boyer David W.Chief Corp. Affairs Officer
Sell826 shares2026-09-14
ABERNETHY MATTChief Financial Officer
Tax Withholding2,709 shares2026-09-11
ABERNETHY MATTChief Financial Officer
Award/Grant5,020 shares2026-09-11
BENEVICH ERICChief Commercial Officer
Tax Withholding3,386 shares2026-09-11
92/ 100
Strong bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
16.7%
Revenue CAGR
53.7%
Current Ratio
3.39x
Return on Equity
14.7%

EPS

EstBeatMiss
$1.97$2.18$2.40$2.61$2.83Q3'25Q3'26
QtrEstActual+/−
Q3'26$2.73 - -
Q3'25$2.07$2.17+4.9%

Revenue

EstBeatMiss
$754M$842M$931M$1.0B$1.1BQ3'25Q3'26
QtrEstActual+/−
Q3'26$1.1B - -
Q3'25 - $795M -

Market Data

NBIX Stock Snapshot

NEUTRAL36/100
$145.51+$0.02 (0.0%)
Market cap
14.68B
P/E ratio
20.8
Day range
$141.39 – $145.77
News sentiment
63/100 · Bullish
Analyst target
$207.81 (+42.8%)
Consensus
Buy · 38 analysts
52-week range+19.1% off low · -24.7% from high
$122.13$193.25
Price $145.51 DailyIQ Est. $217.60

Neurocrine Biosciences Inc. is consolidating: price is in the lower half of its 52-week range without a decisive push either way. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Behaviour On Record

What NBIX's own history says about today's numbers

Realized volatility (21d)
27.8% 21st pct
Below its peak
-23.7%
vs 200-day average
-2.2%
Up days (1y)
51%

Neurocrine Biosciences Inc. is currently running 27.8% annualised volatility over the last 21 sessions. Measured against NBIX's own 13 years of daily returns rather than a market-wide average, that is the 21st percentile — unusually subdued by its own history, against a typical reading of 37.4%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

NBIX is trading -23.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -34.2%, and the deepest was -46.9% in 2018. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -2.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 33rd percentile — close to the gap it normally carries. Over the past year NBIX closed higher on 51% of sessions, and it is currently 2 sessions into a rising streak.

On October specifically: over 13 years of records, NBIX finished the month higher 8 of 13 times, with a median return of +1.3% and an average of -0.0%. Its strongest month historically has been January at +11.8% on average, its weakest September at -3.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: NBIX has opened more than 2% away from the prior close in 191 of 3,267 sessions (5.8% of the time), with the largest gaps running +10.0% and -26.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against NBIX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of NBIX's sector?

Neurocrine Biosciences Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, NBIX ranks 11th of 15 tracked industries, lagging.

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
27
Industry rank
#11 of 15

Options Market

What is the options market pricing for NBIX?

CallsPuts

For Neurocrine Biosciences Inc.'s nearest expiry (2026-11-20, 44 days out), open interest is roughly balanced between puts and calls (put/call ratio of 1.00).

Put/call ratio (2026-11-20)
1.00
Total open interest
2

Analyst Rating Changes

Are analysts turning bullish or bearish on NBIX?

UBS most recently reiterated its rating on Neurocrine Biosciences Inc. to Buy on Sep 29, 2026 with a price target of $214 (from $231). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
UBS — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 29, 2026UBSMaintainedBuy$231 → $214
Sep 11, 2026Morgan StanleyMaintainedEqual-Weight$182 → $183
Sep 8, 2026RBC CapitalReiteratedOutperform$198
Sep 3, 2026CitigroupMaintainedBuy$249 → $253
Aug 13, 2026Morgan StanleyMaintainedEqual-Weight$196 → $182
Aug 3, 2026Canaccord GenuityMaintainedBuy$200 → $210
Aug 3, 2026Truist SecuritiesMaintainedBuy$200 → $213
Aug 3, 2026WedbushMaintainedOutperform$185 → $194
Jul 31, 2026CitigroupMaintainedBuy$246 → $249
Jul 31, 2026RBC CapitalMaintainedOutperform$195 → $198
Jul 31, 2026Morgan StanleyMaintainedEqual-Weight$193 → $196
Jul 31, 2026TD CowenMaintainedBuy$200 → $220

News Sentiment Analysis

Sentiment gathered from recent headlines

63/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Guggenheim analyst Delma Caiati upgraded Neurocrine Biosciences (NBIX) to a Buy rating and announced a new price target of $207. The upgrade reflects confidence in the company’s pipeline and recent clinical progress. The new target represents a significant upside from current market levels, suggesting potential upside for investors.
What did this article say?
ChartMill evaluated Neurocrine Biosciences (NBIX) and assigned it a 7 out of 10 fundamental rating. The assessment highlighted robust growth prospects, solid profitability, and attractive valuation metrics. The analysis positioned NBIX as a solid value play within the biotech sector. The rating suggests that the company’s fundamentals support a favorable investment outlook.
What did this article say?
Neurocrine Biosciences reported robust earnings per share growth, maintaining high profitability with 98% gross margins. The company operates with no debt, reinforcing its financial stability. These factors align with an affordable growth profile, suggesting a solid valuation basis for investors.
What did this article say?
Neurocrine Biosciences announced it would present new research on Prader‑Willi syndrome and real‑world data on its VYKAT® XR drug at the Foundation for Prader‑Willi Research 2026 Annual Symposium. The company highlighted two observational studies—PWS‑VISTA and BRAVE‑PWS—that aim to gather longitudinal evidence and caregiver insights on hyperphagia treatment. The presentation is intended to deepen understanding of the disease and support ongoing clinical development of VYKAT® XR.
What did this article say?
UBS analyst Ashwani Verma reduced Neurocrine Biosciences’ price target from $231 to $214 while keeping a Buy recommendation. The downgrade reflects a reassessment of the company’s valuation relative to peers and market conditions. The move signals a modest negative outlook for NBIX’s near‑term upside potential.
What did this article say?
Neurocrine Biosciences announced that Eiry Roberts would return as chief medical officer, effective immediately. Roberts had previously held the role and also served as a strategic adviser. The appointment follows the departure of Sanjay Keswani, who will leave the company.
What did this article say?
Neurocrine Biosciences announced on September 28, 2026 that Dr. Eiry W. Roberts would return as Chief Medical Officer, effective immediately, following the departure of Dr. Sanjay Keswani. Dr. Roberts previously served as CMO from 2018 to 2025 and has overseen key programs such as INGREZZA® and CRENESSITY®. Her reappointment is expected to reinforce the company’s clinical development strategy and maintain continuity in its therapeutic pipeline.
What did this article say?
Neurocrine Biosciences highlighted its commercial growth priorities, noting China’s growing importance for biotech innovation and early‑stage assets. CEO Kyle Gano emphasized the need to diversify beyond INGREZZA amid an expected 2029 price hit from Medicare. The company is also advancing AI tools to improve productivity and clinical execution across its pipeline.
What did this article say?
RBC has reduced its price target for Neurocrine Biosciences (NBIX) from $198 to $187 while keeping an outperform rating. The downgrade reflects a reassessment of the company’s valuation, likely due to market expectations or recent earnings guidance. The target cut signals a modest negative outlook for NBIX’s share price in the near term.
What did this article say?
Neurocrine Biosciences announced Phase‑4 KINECT‑PRO results showing that 58% of patients achieved symptomatic remission on INGREZZA for tardive dyskinesia, a patient‑reported benefit not captured by traditional scales. The data were released just weeks after a quarterly report that highlighted broader business acceleration, suggesting a dual clinical and commercial upswing. These findings reinforce the drug’s value proposition and could support future pricing and reimbursement discussions.

Technical Analysis

Real-time indicators across multiple timeframes

36
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
2 tracked managers · $50.33M combined position · 0 adding, 0 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Sarissa Capital Management LP• Hold303,1510.30%$38.10M2025-08-14
Citadel Advisors LLC• Hold72,5630.07%$12.23M2026-09-02
Q2 2026 flow:72.6K sh bought ($12.23M)0 sh sold ($0)net +72.6K sh (+$12.23M)
Congressional Trading Activity
1 disclosed trades · ~$8.0K est. traded value · 1 buys, 0 sells
MemberChamberStateTypeAmountTradedFiled
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-112025-08-13